However, the use of CDK4/6 inhibitors (CDK4/6i) can result in cell overgrowth, activation of p53 due to osmotic and replication stress, and an increase in its downstream target, p21, which promotes permanent cell cycle exit and induces senescence in cancer cells [95]. This evidence concerns the gene TP53 and cancer.